5-Phenoxytryptamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
5-Phenoxytryptamine (5-PhO-T), also known as OVT2 or Otava 3736689, is a psychedelic drug of the tryptamine family related to 5-methoxytryptamine (5-MT; 5-MeO-T).[1][2] It is the derivative of tryptamine and 5-methoxytryptamine in which there is a phenoxy group at the 5 position.[2] The drug acts as a biased agonist of the serotonin 5-HT2A receptor, favoring Gαi signaling over Gαq and β-arrestin1 signaling, though not favoring Gαq signaling over β-arrestin2 signaling.[1][2] Its affinity (Ki) for the serotonin 5-HT2A receptor is 57.5 nM and its activational potency at this receptor ranges from 0.28 nM to 15,800 nM and efficacy ranges from 30% to 91% depending on the downstream signaling pathway.[2] OTV2, given via intracerebroventricular injection, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2] In addition, it produces long-term memory deficits that are dependent on serotonin 5-HT2A receptor activation in rodents.[2] The drug was first described in the scientific literature by Elk Kossatz and colleagues in 2024.[1][2] Other related compounds include OTV1, Met-I, and Nitro-I.[1][2]
- None
| |
| Clinical data | |
|---|---|
| Other names | 5-Phenyloxytryptamine; 5-PhO-T; OVT2; OVT-2; Otava 3736689 |
| Drug class | Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H16N2O |
| Molar mass | 252.317 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
